Reposted by Anthony Panozzo
Full Retatrutide phase 3 obesity data published today. It's gonna take a minute to fill dissect this. The appendix alone has 70 pages of data. Long story short we created a drug that's almost too good. Huge chunks of people stopped or reduced doses from excess weight reductions.
nejm.org
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity | NEJM
Retatrutide is a triple-receptor agonist of glucose-dependent insulinotropic polypeptide,
glucagon-like peptide-1, and glucagon receptors. In this phase 3, randomized, double-blind
trial, we assign...